Publication | Closed Access
Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study
11
Citations
10
References
2016
Year
The RR of cetuximab plus chemotherapy of> 45% and the promising PFS rates are strong arguments for clinically testing this combination and this treatment schedule further in R/M HNSCC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1